📜 INTRODUCTION:

In the case Aristo Pharmaceutical Private Limited v. Healing Pharma India Private Limited & Others, the Bombay High Court was confronted with an intriguing intellectual property dispute emerging from the pharmaceutical industry, where trademark protection frequently intersects with public health imperatives. Aristo Pharmaceutical, the applicant, sought an interim injunction alleging that Healing Pharma India Pvt. Ltd. had infringed its registered trademark “ACECLO” by adopting and marketing pharmaceutical compositions under the brand names “ACECLOHEAL-MR,” “ACECLOHEAL-SP,” and “ACECLOHEAL-PLUS.” Aristo asserted that its mark, in continuous commercial use since 2003, had garnered wide recognition and substantial goodwill, particularly through sales exceeding Rs 42 crore during the relevant period. The plaintiff accused Healing Pharma of dishonest and deceptive adoption designed to ride on its established reputation and divert its customer base. Healing Pharma, on the other hand, maintained that “ACECLO” was no proprietary or invented term, but merely a clipped and descriptive form derived from the globally recognised International Non-Proprietary Name (INN) Aceclofenac, a generic anti-inflammatory agent. The case raised a crucial and evolving legal question—whether pharmaceutical companies may claim exclusive rights over abbreviations, truncated forms, or formative adaptations of INNs, which are expressly intended to remain part of the public domain, and whether such derived marks can be monopolised under the Trade Marks Act, 1999. The Court’s adjudication of this interim relief application thus carried significance beyond the immediate parties, potentially affecting pharmaceutical naming conventions, regulatory practices, industry competition, and public access to medicines.

⚔️ ARGUMENTS:

The plaintiff, Aristo Pharmaceutical Private Limited, contended that its registered trademark “ACECLO” had acquired distinctiveness through long-term, continuous, and extensive commercial use since 2003, making it uniquely associated with its products across the pharmaceutical market. Aristo argued that the mark was not a direct adoption of the INN Aceclofenac but a coined and distinctive expression, the fruit of its marketing and branding efforts, and had thus transcended descriptive origins to achieve secondary meaning. Relying on its substantial sales figures, promotional expenditure, and consumer recognition, Aristo maintained that Healing Pharma’s adoption of marks such as “ACECLOHEAL-MR,” “ACECLOHEAL-SP,” and “ACECLOHEAL-PLUS” was neither bona fide nor original, but instead a deliberate and dishonest attempt to exploit Aristo’s established brand identity, causing confusion among chemists, medical practitioners, and end-users. It insisted that even minor variations or additions like suffixes could not protect an infringer who adopts an essential portion of a registered mark, particularly in medicines, where confusion could lead to grave health hazards. Aristo alleged that the defendants intentionally embellished their products with identical or deceptively similar prefixes, thereby capitalising on its brand equity and leading consumers to believe that the defendant’s products were connected with, or emanated from, Aristo. Conversely, Healing Pharma India Pvt. Ltd. vigorously disputed these allegations, contending that “ACECLO” cannot be monopolised as it is evidently and undeniably derived from the INN Aceclofenac, which is globally recognised, generic, descriptive, and legally prohibited from being registered under Section 13 of the Trade Marks Act, 1999. Healing Pharma asserted that international pharmaceutical nomenclature standards demand that INNs remain available for universal reference, identification, and use, ensuring that drug names are accessible to manufacturers, doctors, and patients alike without proprietary constraints. Therefore, any attempt to assert exclusivity over an INN-derived mark contravenes public interest and statutory prohibitions. The defendant maintained that its mark “ACECLOHEAL” adds a unique and distinguishable suffix that reflects its corporate identity, creating a visual and conceptual divergence sufficient to eliminate confusion. It further argued that Aristo’s claim lacked evidentiary support, as no consumer complaints, mis-prescriptions, or documented cases of confusion were produced. Healing Pharma emphasised that price disparity, packaging differences, unique typography, colour scheme variations, and brand placement further diminished the likelihood of substitution or deception. It contended that Aristo’s grievance was speculative and driven more by a desire to stifle legitimate competition than to protect genuine intellectual property rights. The defendant also maintained that the plaintiff, despite alleging dishonest adoption, had failed to establish any intent on its part to appropriate Aristo’s goodwill, and thereby did not satisfy the legal criteria necessary for grant of interim injunction, such as prima facie case, irreparable injury, and balance of convenience, rendering the injunction application unsustainable.

⚖️ JUDGMENT:

The Bombay High Court, presided over by Justice Sharmila U. Deshmukh, declined to grant the interim injunction sought by Aristo Pharmaceutical, ruling that no pharmaceutical entity can monopolise a trademark derived from an International Non-Proprietary Name (INN), reaffirming that such names and their variants lie firmly within the public domain. The Court observed that Section 13 of the Trade Marks Act, 1999 expressly prohibits the registration of INNs or deceptively similar names, as these designations are intended to serve as universally understood chemical identifiers, rather than private commercial assets capable of exclusive appropriation. Justice Deshmukh held that “ACECLO” was merely a clipped, descriptive abbreviation derived from Aceclofenac, and hence inherently publici juris, non-distinctive, and incapable of generating statutory monopoly. The Court reasoned that even where registration existed, the prohibition under Section 13 operates independently of a defendant’s challenge to the mark’s validity, making exclusivity claims unsustainable. It further noted that both competing marks—ACECLO and ACECLOHEAL—emanated from the same INN, rendering traditional deceptive similarity tests inapplicable, because when competing marks originate from a shared descriptive source, the plaintiff cannot claim proprietary ownership over the common component. The Court examined the product packaging, trade dress, brand presentation, and price variations, finding them sufficiently distinct to dispel any realistic apprehension of consumer confusion or illicit substitution. It dismissed speculative assertions about chemists’ conduct, remarking that injunctions cannot be granted on conjectures unsupported by empirical evidence. Since Aristo failed to establish a prima facie case, demonstrate irreparable harm, or show that the balance of convenience tilted in its favour, the request for interim protection was rejected. The ruling reinforced a core tenet of pharmaceutical trademark jurisprudence—that INN-derived marks cannot be privatised, and public health considerations, market competition, and nomenclature clarity must supersede commercial exclusivity claims, thereby dismissing the application and allowing Healing Pharma to continue marketing its products.